US government lifts suspension on PharmAthene's anthrax funding
This article was originally published in Scrip
Executive Summary
PharmAthene is to resume the development of its anthrax vaccine SparVax under an agreement with the Biomedical Advanced Research and Development Authority (BARDA) after the US Government Accountability Office (GAO) denied a competitor's protest over a contract modification.